Laurent BERTOLETTI

Assessing Tilt and Retrieval Challenges with Inferior Vena Cava Filters: Comparison of Original and Anti-Tilting Models of the ALN Filter To compare the tilt of the classical ALN® inferior vena cava filter (IVCF) with that of the new Optional Anti-Tilting Filter (OATF) in a single-center retrospective study.

Assessing Tilt and Retrieval Challenges with Inferior Vena Cava Filters: Comparison of Original and Anti-Tilting Models of the ALN Filter - Journal of Vascular and Interventional Radiology www.jvir.org/article/S105...

Illustration showing Functional Venous Insufficiency and Venous Hypertension. Along left side of image reads the following: Clinical Practice Nonsurgical Management of Chronic Venous Insufficiency Eri Fukaya, M.D., Ph.D., and Raghu Kolluri, M.D. Published December 18, 2024

Chronic venous insufficiency is mainly due to venous hypertension, the cause of which can be structural or functional. Treatment is aimed at decreasing venous hypertension through conservative, nonprocedural management.

Learn more in this December 2024 Clinical Practice article: nej.md/41Zd5Av

🗞 Article du Parisien : les Doyennes et Doyens de médecine, le syndicat étudiant ANEMF et l’Ordre des médecins se sont opposés au projet du ministre de la Santé de réintégrer les jeunes français partis étudier à l’étranger.
https://swll.to/h4Za9F

Assessing Tilt and Retrieval Challenges with Inferior Vena Cava Filters: Comparison of Original and Anti-Tilting Models of the ALN Filter To compare the tilt of the classical ALN® inferior vena cava filter (IVCF) with that of the new Optional Anti-Tilting Filter (OATF) in a single-center retrospective study.

Assessing Tilt and Retrieval Challenges with Inferior Vena Cava Filters: Comparison of Original and Anti-Tilting Models of the ALN Filter - Journal of Vascular and Interventional Radiology www.jvir.org/article/S105...

Les universités, elles, sont sous tension. « On est au maximum de ce qu'on peut faire avec nos moyens », alerte Isabelle Laffont, doyenne de la faculté de médecine de Montpellier-Nîmes. Salles trop petites, manque de matériel, de places dans les restaurants universitaires, d'enseignants chercheurs, les difficultés sont légion. La Conférence des doyens de médecine, qu'elle préside, estime qu'il manquerait 500 enseignants pour encadrer les 12 000 étudiants attendus à la rentrée 2025.

Dans Le Pélerin, Isabelle Laffont à propos de la suppression du numerus apertus : www.lepelerin.com/france/sante...

😱 quel succès pour la future Edition de la Journée Stéphanoise de Vasculaire !

En moins de 3 semaines, les capacités d'accueil sont déjà remplies aux 2 tiers 👏

⌚ dépêchez vous pour les dernières places, à la différence des années précédentes, il ne sera pas possible de "pousser les murs"

Thank you for your comment.
I suggest you read the article (it is available if you wish, by DM).
You will see that we evaluated the inflammatory response of a cell model to specify the effect of different flavors and heat.
Without any industrial funding.
In an academic team
For a PhD.

Flavor-induced inflammation and cytotoxicity in human aortic smooth muscle cells: Potential implications for E-cigarette safety Electronic nicotine delivery systems (ENDS), commonly known as e-cigarettes, are considered safer alternatives to tobacco smoking, yet their long-term…

E-cigarettes are seen as safer, but they can trigger inflammatory responses linked to vascular events. Kudos to M. Bitar, V Forest and the SAINBIOSE team for studying the effects of condensates and flavors!
#vascular

www.sciencedirect.com/science/arti...

C'est le plan de la dernière chance avant des mesures "plus radicales". Ce 25 avril, le Premier ministre a présenté son pacte de lutte contre les déserts médicaux.

Le détail de ce plan ➡️ tinyurl.com/358erfn5

✍ Clémence Nayrac

a cartoon of a man doing push ups with the words rule 1230 seriously though train hard below him ALT: a cartoon of a man doing push ups with the words rule 1230 seriously though train hard below him

Le soleil est de retour ! Mais ce n est pas une raison pour ne pas s entraîner ;-) le dossier de mai est dispo 👇 therap.fr/mai-2025/

Changes in Inhaled Steroid Dispensing to Children After Withdrawal of Brand-Name Fluticasone Propionate This study evaluates whether the market withdrawal of brand-name fluticasone propionate was associated with discontinuation of inhaled steroid therapy in children.

Always surprised for a Franco-European culture to see these market reasoning for a drug effective on morbidity and mortality, including infant mortality

jamanetwork.com/journals/jam...

😱 quel succès pour la future Edition de la Journée Stéphanoise de Vasculaire !

En moins de 3 semaines, les capacités d'accueil sont déjà remplies aux 2 tiers 👏

⌚ dépêchez vous pour les dernières places, à la différence des années précédentes, il ne sera pas possible de "pousser les murs"

En tant qu’auteur du rapport « La financiarisation de l’offre de soins, une OPA sur le système de santé ? », j’ai étudié ce phénomène économique qui risque de faire primer la logique de gain sur le soin.

🧶 1/3

Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-labe... In patients with venous thromboembolism requiring extended anticoagulation, reduction of the direct oral anticoagulant dose did not meet the non-inferiority criteria. However, the low recurrence rates...

The RENOVE trial found that while low-dose DOACs did not meet non-inferiority for preventing recurrent VTE, it showed a better risk-benefit ratio, with less clinically relevant bleeding. Dose reduction may be a good option for many patients!
www.thelancet.com/journals/lan...
@thelancet.bsky.social

Prof. @isabellemahe.bsky.social presents API-CAT at @accintouch.bsky.social published in @nejm.org: Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in cancer patients
www.nejm.org/doi/full/10....

🚨 SAVE THE DATE ! 🚨
La 3ᵉ Journée Stéphanoise de Vasculaire arrive ! 🔬🩸
Au programme :
✅ Pathologies artérielles, veineuses & lymphatiques
✅ Thérapeutiques innovantes
✅ Peter Verhamme en invité d'honneur !
⤵️

#JSV2025 @gpoenou.bsky.social

🚨 SAVE THE DATE ! 🚨
La 3ᵉ Journée Stéphanoise de Vasculaire arrive ! 🔬🩸
Au programme :
✅ Pathologies artérielles, veineuses & lymphatiques
✅ Thérapeutiques innovantes
✅ Peter Verhamme en invité d'honneur !
⤵️

#JSV2025 @gpoenou.bsky.social

Acute exacerbation of chronic obstructive pulmonary disease: An underestimated cardiovascular risk factor

🔬 COPD exacerbations: a cardiovascular ticking time bomb? 🫁❤️

A new meta-analysis underscores a significant ↗️ in #cardiovascular events during acute #COPD exacerbations.

Our latest editorial, written with Dr Valentine MISMETTI

www.sciencedirect.com/science/arti...

@sevestrema.bsky.social @laurentbertoletti.bsky.social
Le nouveau podcast du cemv

La médecine basée sur les preuves : un rempart contre le charlatanisme La médecine basée sur les preuves permet de mieux évaluer l’efficacité des traitements médicaux. Mais elle n’est pas encore suffisamment prise en compte, comme en témoigne le succès de l’homéopathie.

La médecine basée sur les preuves : un rempart contre le charlatanisme
theconversation.com/la-medecine-...

28 ans d’émissions de CO2 évitées grâce au nucléaire, à quand le sursaut stratégique ? INFO LE POINT. Dans une étude que « Le Point » dévoile en exclusivité, l’institut Molinari s’alarme de l’enlisement de la filière nucléaire française, malgré les promesses de Macron.

INFO LE POINT. 28 ans d’émissions de CO2 évitées grâce au nucléaire, à quand le sursaut stratégique ? Dans une étude que « Le Point » dévoile, l’@iem_molinari s’alarme de l’enlisement de la filière nucléaire, en dépit des promesses. www.lepoint.fr/tiny/1-2583786

YouTube video by MARKUS at HOMe Venous Thromboembolism in Cancer Patients - Prof. Laurent Bertoletti (Saint-Étienne, France)

Also watch our past webinar with @laurentbertoletti.bsky.social , one of the co-authors of the article, about venous thromboembolism in cancer patients on our YouTube channel!

youtu.be/f6Xc3X5oVkk?...

The emerging role of anticoagulants targeting Factor XI in thromboembolism management Published in Expert Review of Respiratory Medicine (Ahead of Print, 2025)

🩸🔬 Discover how targeting Factor XI can improve patient care in thromboembolism.

@gpoenou.bsky.social @chu-st-etienne.fr

#cancer #thrombosis

Full article: The emerging role of anticoagulants targeting Factor XI in thromboembolism management www.tandfonline.com/doi/full/10....

🎉 Retour sur les 10 ans du Campus Santé Innovations de Saint-Étienne !

Ce matin, nous avons célébré une décennie d’innovation et de collaboration. Merci au Pr Didier SAMUEL, Président de l’INSERM, pour son intervention, et à tous les participants pour ce moment exceptionnel.

Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation | NEJM Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in pati...

“Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation." 
Publié ce jour dans le @nejm.org.
#Medsky #Cardiology
www.nejm.org/doi/full/10....

Figure showing limitations and challenges to key steps in the design and interpretation of research on emergent technologies. Copyright: 2024 Elsevier Ltd. All rights are reserved.

More needs to be done to prepare future generations to safely interact with artificial intelligence.

In The Lancet Child & Adolescent Health, experts call for new, collaborative policy action to protect children & adolescents against the potential mental health harms of AI: tinyurl.com/492fmye2

Rewards for Frequent Reviewers All reviewers who complete at least three reviews of appropriate quality and timeliness for one IDSA journal in a calendar year will be rewarded the following calendar year with their choice of either free page charges in CID or JID, or a 20% discount on open access fees in any IDSA journal. These rewards can be claimed with any IDSA journal, not just the journal where the reviews were performed. In addition, we are including our top 100 most frequent reviewers from 2020-2023 for the launch of this rewards program as a small way to thank the ID community for all of the time and energy they poured into review for the IDSA journals during the height of the COVID pandemic.

Recognition for Top Reviewers Each journal will recognize its best reviewers, selected based on number of reviews completed, timeliness and review quality, with recognition letters each quarter. In addition, the top three reviewers from each journal will be recognized with a "Reviewer of the Year" award. Our Reviewers of the Year will receive paid registration to IDWeek and will be invited to attend the IDSA Editor's Reception at IDWeek, in addition to recognition in the MyIDSA Community, IDSA News, our journal social media channels, and elsewhere.

IDSA journals launch Reviewer Recognition & Rewards program

Reviewers of 3+ papers in 1 IDSA journal in a yr get waived page charges in CID/JID, or 20% discount on OA fees

Top 3 reviewers (per J) get “Reviewer of the Year” distinction & IDWeek registration

academic.oup.com/idsa/pages/i... #IDSky

The #RIETEregistry experience on patients with acute VTE and thrombocytopenia at baseline

Find it here: pubmed.ncbi.nlm.nih.gov/39791523/

My favorite Sankey diagram 😍
After one VTE recurrence, the main issue is ... another VTE recurrence !

@rpth.bsky.social @isth-official.bsky.social

Occurrence and management of thrombosis recurrence and bleeding in low-molecular-weight heparin-treated patients with cancer-associated thrombosis: a French nationwide cohort study Rates of venous thromboembolism (VTE) recurrence and bleeding remain high in patients with cancer who are prescribed anticoagulants (ACs) such as low-molecular-weight heparin (LMWH) after an initial V...

📣 #VTE in patients with #cancer: 1️⃣ in 🔟 experiences thrombotic and/or bleeding complications during follow-up under #anticoagulant therapy 😢

❓ Management of these events remains poorly standardized.

Read our findings here ⤵️ :
www.rpthjournal.org/article/S247...